Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-FR Version v4-FR
Language French French
Date Updated 2019-08-12 2019-08-12
Drug Identification Number 00865109 00865109
Brand name DIANEAL PD4 CAPD SOLUTION WITH 2.5% DEXTROSE AND 2.5MEQ/L CALCIUM DIANEAL PD4 CAPD SOLUTION WITH 2.5% DEXTROSE AND 2.5MEQ/L CALCIUM
Common or Proper name DIANEAL PD4 CAPD SOLUTION WITH 2.5% DEXTROSE AND 2.5MEQ/L CALCIUM DIANEAL PD4 CAPD SOLUTION WITH 2.5% DEXTROSE AND 2.5MEQ/L CALCIUM
Company Name BAXTER CORPORATION BAXTER CORPORATION
Ingredients SODIUM LACTATE DEXTROSE MAGNESIUM CHLORIDE CALCIUM CHLORIDE SODIUM CHLORIDE SODIUM LACTATE DEXTROSE MAGNESIUM CHLORIDE CALCIUM CHLORIDE SODIUM CHLORIDE
Strength(s) 448MG 2.5G 5.08MG 18.3MG 538MG 448MG 2.5G 5.08MG 18.3MG 538MG
Dosage form(s) SOLUTION SOLUTION
Route of administration DIALYSIS DIALYSIS
Packaging size 3L Twinbag 3L Twinbag
ATC code B05ZA B05ZA
ATC description HEMODIALYTICS AND HEMOFILTRATES HEMODIALYTICS AND HEMOFILTRATES
Reason for discontinuation Business reasons Business reasons
Anticipated discontinuation date 2020-03-31 2020-03-31
Actual discontinuation date
Remaining supply date 2020-03-31 2020-03-31
Discontinuation status To be discontinued To be discontinued
Discontinuation decision reversal no no
Information on remaining supply
Company comments Prescribers will have the option to make prescription adjustments to accommodate alternate fill offerings and assess suitability for APD. Patients requiring calcium supplementation can also obtain this through alternate routes such as the oral, IV or IP route. It is up to the healthcare professional to decide on the best dose and route of administration of calcium supplements for their patient. Prescribers will have the option to make prescription adjustments to accommodate alternate fill offerings and assess suitability for APD. Patients requiring calcium supplementation can also obtain this through alternate routes such as the oral, IV or IP route. It is up to the healthcare professional to decide on the best dose and route of administration of calcium supplements for their patient.
Health Canada comments